Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2021-01-26 Foreign Filer Report
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
SYMBICORT APPROVED IN CHINA FOR MILD ASTHMA
Foreign Filer Report
2021-01-26 English
Symbicort approved in China for mild asthma
Regulatory Filings Classification · 100% confidence The document begins with 'RNS Number : 8851M' and is dated '26 January 2021'. It announces a specific corporate event: the approval of Symbicort Turbuhaler in China. The text concludes with standard boilerplate language referencing 'RNS, the news service of the London Stock Exchange' and the 'Financial Conduct Authority'. This structure is characteristic of a general regulatory news service announcement, which falls under the 'Regulatory Filings' category (RNS) as it is not a specific financial report (like 10-K, ER, or IR) but rather a broad market disclosure. Given the document length (13,196 chars) and the content being a specific news announcement rather than a placeholder stating a report is attached, it is not an RPA. It is a specific regulatory disclosure that doesn't fit the other detailed categories (like DIV, DIRS, MANG, etc.). Therefore, the most appropriate classification is RNS.
2021-01-26 English
CALQUENCE APPROVED IN JAPAN FOR CLL
Foreign Filer Report
2021-01-25 English
CALQUENCE MET PRIMARY EFFICACY ENDPOINT IN HEAD-TO-HEAD TRIAL AGAINST IBRUTINIB
Foreign Filer Report
2021-01-25 English
Calquence approved in Japan for CLL
Earnings Release Classification · 99% confidence The document begins with an 'RNS Number' and a date, indicating it is a regulatory announcement disseminated via the RNS service of the London Stock Exchange. The content details a specific corporate event: the approval of the drug Calquence in Japan for a specific medical condition. This type of announcement, which is a material update about product/market development rather than a full financial report (like 10-K or IR) or a transcript, fits best under the general category for regulatory announcements that do not fit other specific categories. Since it is a formal announcement of a significant event (drug approval) released through the official regulatory news service (RNS), it is classified as a Regulatory Filing (RNS). It is not an Earnings Release (ER), Interim Report (IR), or a specific legal/capital/management update, making RNS the most appropriate fallback/general regulatory category. Q1 2021
2021-01-25 English
Calquence met primary endpoint against ibrutinib
Regulatory Filings Classification · 99% confidence The document begins with 'RNS Number : 7284M' and is dated '25 January 2021 07:00 GMT'. It contains a headline about clinical trial results ('Calquence met primary efficacy endpoint...') and concludes with boilerplate text stating, 'This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' This structure is characteristic of a regulatory news service announcement, which falls under the general category of Regulatory Filings (RNS), as it is an immediate, non-periodic disclosure of material information.
2021-01-25 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.